BMS Inks $850M Cancer Drug Deal
Bristol Myers Squibb is partnering with Janux Therapeutics in an $850 million collaboration to develop next-generation cancer treatments. The deal, which includes an exclusive license agreement, is focused on creating tumor-activated therapeutics, a promising approach in oncology.
The agreement provides Janux Therapeutics with $50 million in upfront and near-term milestone payments. The deal also includes the potential for an additional $800 million in payments based on development, regulatory, and commercial milestones, along with tiered royalties on global sales. This collaboration centers on Janux's proprietary Tumor Activated T Cell Engager (TRACTr) platform. This technology is designed to overcome the limitations of traditional T-cell engager therapies by keeping the therapeutic "masked" and inactive until it reaches the tumor microenvironment, which could reduce toxicity in healthy tissues. For Bristol Myers Squibb, this deal is part of a broader strategy to strengthen its oncology pipeline, especially as it faces patent expirations for key drugs. The company has been actively pursuing partnerships and acquisitions to bring in innovative technologies and next-generation cancer treatments. San Diego-based Janux Therapeutics is a clinical-stage biotech company that went public in 2021. This deal is seen by analysts as a significant validation of Janux's technology platform. The company also has an existing collaboration with Merck to develop other TRACTr candidates. Under the terms of the agreement, Janux will handle the preclinical development of the new cancer therapy. Once the drug is ready for clinical trials, Bristol Myers Squibb will take over responsibility for its development and commercialization, with Janux providing support through the initial Phase 1 study. The market for T-cell engaging therapies is a rapidly growing segment of the oncology market, with analysts predicting a compound annual growth rate of over 20%. This growth is driven by advancements in immunotherapy and the potential for these therapies to treat a wide range of cancers, including solid tumors which have historically been difficult to treat with this approach. Following the announcement, Janux Therapeutics' stock (NASDAQ: JANX) saw a significant surge, climbing 12-14%. Analysts have issued "strong buy" ratings for the company, citing the Bristol Myers Squibb partnership as a key factor.
